**Centers for Disease Control and Prevention** National Center for Immunization and Respiratory Diseases



## Overview of Long COVID: Epidemiology and Public Health Approach

Sharon Saydah, PhD MHS Priti Patel, MD, MPH

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.


## **Objectives**


- Provide an update on COVID-19 and other respiratory viruses
- Outline a framework for understanding Post-COVID Conditions or Long COVID
- Estimate the occurrence of Long COVID
- Discuss the role of health officials and health departments

# **Respiratory Virus Update**


## Level of Respiratory Illness Activity

- Amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated across many areas of the country
- For the week of February 19<sup>th</sup>, 27 jurisdictions experienced high or very high activity
- The number remains stable compared to the previous week





**Emergency Department Visits for Viral Respiratory Illness:** Weekly percent of total emergency department visits associated with COVID-19, influenza, and Respiratory Syncytial Virus



Data presented through: 02/17/2024; Data as of: 02/21/2024 <u>Respiratory Virus Activity Levels (cdc.gov)</u>

# Long COVID: Framework

## A general framework for Post-COVID Conditions

Wide range of physical and mental health consequences continue or develop at **least 4 weeks initial SARS-CoV-2 infection** 

## Post acute sequelae of SARS-CoV-2 infection (PASC)

- System specific pathology (e.g. lung fibrosis, stroke)
- Clinically significant symptoms with unclear pathology (e.g. ME/CFS\*-like, dysautonomia)
- On-going symptoms following MIS-C\*\*

# General consequences of illness and hospitalization

- Post ICU syndrome
- Other complications of treatment or illness

Conditions frequently overlap Patients may experience any combination

Long COVID is a commonly used term for Post-COVID Conditions

\*ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome \*\* MIS-C: Multisystem Inflammatory Syndrome in Children

## **Common Symptoms reported for Post-COVID conditions**

#### **General symptoms**

- Tiredness or fatigue that interferes with daily life
- Symptoms that get worse after physical or mental effort (also known as "post-exertional malaise")

#### Cardiovascular and Respiratory symptoms

- Dyspnea/shortness of breath
- Cough
- Chest pain
- Heart palpitations

#### Digestive symptoms

- Diarrhea
- Stomach pain

#### Long COVID or Post-COVID Conditions | CDC

#### **Neurological symptoms**


- Difficulty thinking or concentrating (sometimes referred to as "brain fog")
- Headache
- Sleep problems
- Dizziness when standing up (lightheadedness)
- Pins-and-needles feelings
- Change in smell or taste
- Depression or anxiety

#### Other symptoms


- Joint or muscle pain
- Rash
- Changes in menstrual cycles

Over 200 symptoms have been reported by people with Long COVID

# Post-COVID Conditions and symptoms impact multiple organ systems with differing pathology



### Multiple proposed potential mechanisms for Post-COVID conditions



Proposed mechanisms could include


- viral persistence
- systemic and tissue-specific inflammation
- auto immunity
- microvascular dysfunction

Proposed contributing mechanisms

Trends in Immunology

Peluso and Deeks. Early clues regarding the pathogenesis of long-COVID: Trends in Immunology (cell.com) 2022

# Long COVID: Epidemiology



Analysis of National Health Interview Survey Long COVID data for children Read the report. Analysis of National Health Interview Survey Long COVID data for adults Read the report.

In 2022, 6.9%

of adults

had ever had

Long COVID

bit.ly/NCHS1027


www.cdc.gov/nchs

Long COVID in Adults, United States 2022

CDC


Long COVID in Children, United States 2022

# Prevalence of report of experiencing Long COVID among adults ≥ 18 years by jurisdiction- 2022



# Adults with Long COVID report significant activity limitations


### Almost 1 in 4 adults with Long COVID report significant activity limitations



Long COVID and Significant Activity Limitation Among Adults, by Age — United States, June 1–13, 2022, to June 7–19, 2023

# Time to symptom end date among those who tested positive for SARS-CoV-2 by variant period, REACT study

- 133,526 adults reporting SARS-CoV-2 infection
- Mean duration of COVID related symptoms 1 to 3 weeks
- 7.5% reporting symptoms at 12 weeks
- 5.4% reporting symptoms at 52 weeks



Long-term health impacts of COVID-19 among 242,712 adults in England | Nature Communications


## Persistent symptoms of Long COVID among children

- Difficulties in assessing Long COVID in young children include:
  - Inability of younger children to verbalize symptoms
  - Inconsistent manifestation of symptoms
  - Assessments of conditions may be dependent on expected developmental milestones
- Among children identified in emergency departments:
  - Absolute risk of ongoing symptoms was low, but greater among those who were SARS-CoV-2 positive (0.42% at 6 months and 0.51% at 12 months) and the most common symptoms were respiratory
  - Quality of life reported by participants at 6 and 12 months did not differ by SARS-CoV-2 positivity
- Prevalence difference for persistent symptoms among sero-positive children compared to seronegative children is 4.1%

<u>A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents | Nature Communications</u> <u>A Systematic Review of Persistent Clinical Features After SARS-CoV-2 in the Pediatric Population | Pediatrics | American Academy of Pediatrics (aap.org)</u> <u>Post-COVID-19 Condition in Children 6 and 12 Months After Infection | Pediatrics | JAMA Network Open | JAMA Network</u>

### Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years


- Analysis of occurrence of 26 clinical conditions in EHRs during Mar 2020 – Nov 2021 (~63 million unique adult records)
- Patients followed for 30 365 days after their initial acute COVID index encounter
- 38% of case-patients and 16% controls experienced at least one incident condition



Bull-Otterson et al. Post-COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years – United States, March 2020–November 2021. *MMWR* May 27, 2022.

# Post-COVID-19 Symptoms and Conditions among Children and Adolescents

- Analysis of large medical claims database of children with and without COVID-19 of 46 symptoms and conditions
- During March 1, 2020–January 31, 2022, increased risk of four symptoms and eight conditions 31–365 days following COVID-19 among children aged 0–17 years




See a health care provider if your child is experiencing new or ongoing symptoms after having COVID-19



bit.ly/MMWR7131a3 AUGUST 5, 2022 MMWR

Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 | MMWR (cdc.gov)


#### a) two-dose vaccination vs. no vaccination




**COVID-19** vaccination (1 or 2 doses) reduces **Post-COVID Conditions compared** to no vaccination among those with SARS-CoV-2 infection

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis - ScienceDirect

#### b) two-dose vaccination vs. one-dose vaccination



c) one-dose vaccination vs. no vaccination



## Groups associated with a higher likelihood of developing Long COVID

#### Females

- Older age (sometimes)
  - Adolescents compared to younger children
  - Middle-aged adults compared to younger and older adults for symptoms
  - Older adults compared to younger adults for incident conditions
- Severity of COVID-19 illness
- Underlying health conditions prior to COVID-19
  - Asthma, autoimmune diseases
- Lower socio-economic status
- Did not get COVID-19 vaccine

Maglietta G et al. Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. JCM 2022 Socioeconomic inequalities of Long COVID-UK. Shabnam et al. 2023 (sagepub.com) Hastie. et al. Outcomes among confirmed cases and matched comparison group in the Long COVID in Scotland Study. Nature 2022 Epidemiology of Long Coronavirus Disease in US Adults | Clinical Infectious Diseases | Oxford Academic (oup.com) Frontiers | Hospital admission and vaccination as predictive factors of long COVID-19 symptoms (frontiersin.org) Excess direct medical costs were higher among COVID-19 cases compared to non-COVID controls



Direct medical costs for children 1.75x higher among cases compared to controls



Direct medical costs for adults 1.56x higher among cases compared to controls

**U**@



## US Government Response to Long COVID and Public Health Approach

#### **The Federal Government Response**





There are seven research priorities

- 1. Characterize the full clinical spectrum of Long COVID and diagnostic strategies
- 2. Understand the pathophysiology of Long COVID
- 3. Engage in surveillance and epidemiology to understand burden and risk factors
- 4. Understand impacts on well-being, quality of life
- 5. Develop safe and effective treatments, and other interventions
- 6. Evaluate and improve support services
- 7. Conduct health services and health economics research



### **Agencies Involved in Long COVID Response Efforts**

Department of Defense

Department of Education

Department of Energy

Department of Health and Human Services

Department of Homeland Security/FEMA

Social Security Administration

Office of Personnel Management

Department of Housing and Urban Development

Department of Justice

Department of Labor

Department of the Treasury


Department of Veterans Affairs

Equal Employment Opportunity Commission

National Council on Disability



#### **CDC Organizational Entities Involved in Long COVID**



#### <u>ARTICLE IN PRESS</u>

**Open access** 

American Journal of Preventive Medicine

CURRENT ISSUES

#### The Role of U.S. Public Health Agencies in Addressing Long COVID


Priti R. Patel, MD, MPH,<sup>1,2</sup> Jay R. Desai, PhD, MPH,<sup>3</sup> Marcus Plescia, MD, MPH,<sup>4</sup> Jessica Baggett, MPH,<sup>4</sup> Peter Briss, MD, MPH<sup>5</sup>

ong COVID (or post-COVID conditions) refers to symptoms or health conditions that persist or occur  $\geq$ 4 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<sup>1</sup> Symptoms such as brain fog, fatigue, pain, dyspnea, depression, and a wide range of other manifestations can occur and may be debilitating. The mechanism(s) of these outcomes are poorly understood, creating challenges to prevention and treatment. The study of Long COVID is rapidly evolving, and approaches to describe its burden vary. However, prevalence estimates of activassociated with Long COVID. In April 2023, an online survey was sent to all 59 state and territorial health officials. The survey included multiple-choice and openended questions to determine areas in which jurisdictions were already working, barriers to progress, and priorities for further initiatives. In total, 43 of 59 jurisdictions—including 4 U.S. territories and freely associated states—participated in the survey, resulting in a 73% response rate. Jurisdictions were queried about their current activities and funding and asked to rank their most immediate needs related to Long COVID.





#### **RESEARCH AND GUIDELINES**





#### Jurisdictional Needs to Address Long COVID (N=43)

#### Most immediate needs in rank order:

- (1) The need for a standard definition
- (2) Surveillance efforts and best practices
- (3) Prevention and mitigation
- (4) Access to multidisciplinary care/Long COVID clinics
- (5) Provider engagement and education
- (6) Health system capacity building
- (7) Public communications
- (8) Addressing the mental health impacts of Long COVID
- (9) Policy development

## Only 12% of jurisdictions have Long COVID funding





### National Academies of Sciences, Engineering, and Medicine and Federal Advisory Committee


- Committee to examine current working definitions for Long COVID
  - Report expected in June 2024



Federal Advisory Committee on Long COVID

https://www.nationalacademies.org/our-work/examining-the-working-definition-for-long-covid

## Agency for Healthcare Research and Quality (AHRQ) Long COVID Care Network



Kennedy Krieger Institute, Baltimore, MD University of Pittsburgh, Pittsburgh, PA University of Texas Health Science Center, San Antonio, TX University of Washington, Seattle, WA Icahn School of Medicine at Mount Sinai, New York, NY Emory University, Atlanta, GA University of Colorado, Denver, CO Stanford University, Stanford, CA Washington University in St. Louis, St. Louis, MO


https://www.ahrq.gov/coronavirus/long-covid/care-network.html

## **Resources and Education Outreach**

Building Clinical Capacity Through the Long COVID and Fatiguing Illness Recovery Program



University of Colorado UW Medicine Anschutz Medical Campus Public Program LiECHO



<u>Global Long Covid ECHO Webinar Series: Exploring Clinical</u> <u>Practice and Research | iECHO</u>

## Key takeaways

- Post-COVID Conditions are common following SARS-CoV-2 infection, decrease with time since infection, and have decreased since the start of the pandemic
- Symptoms and conditions associated with Post-COVID Conditions are not unique to having had SARS-CoV-2 infection
- Post-COVID Conditions are associated with increased health care utilization and significant activity limitations
- Accumulating evidence that COVID-19 vaccination reduces Post-COVID Conditions among both children and adults
- Public health organizations are critical to building clinical care capacity, advancing public awareness of Long COVID, and combating stigma.

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 <u>www.cdc.gov</u>

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

